• NICE turns down rare skin disease implant pharmatimes
    December 21, 2017
    The National Institute for Health and Care Excellence has rejected Clinuvel UK’s afamelanotide for treating erythropoietic protoporphyria (EPP) in preliminary guidelines deeming it far too expensive for NHS use.
PharmaSources Customer Service